GLYC
GlycoMimetics Inc
NASDAQ: GLYC · HEALTHCARE · BIOTECHNOLOGY
$0.16
+0.00% today
Updated 2026-04-30
Market cap
$10.13M
P/E ratio
—
P/S ratio
1,095.16x
EPS (TTM)
$-46.00
Dividend yield
—
52W range
$0 – $18
Volume
—
GlycoMimetics Inc (GLYC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.85M | $-10.47M | $-15.54M | $-4.28M | $-8.24M | $-29.73M | $-29.77M | $-43.33M | $-51.98M | $-39.24M | $-57.49M | $-46.46M | $-34.88M | $-31.10M |
| Capital expenditures | $182438.00 | $316180.00 | $82091.00 | $212603.00 | $268594.00 | $704202.00 | $294107.00 | $125618.00 | $144928.00 | $68507.00 | $14943.00 | $84191.00 | $21394.00 | $9972.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $376243.00 | $415208.00 | $425689.00 | $1.64M | $2.32M | $2.96M | $3.76M | $4.59M | $6.22M | $6.90M | $6.09M | $3.86M | $3.56M | $4.77M |
| Free cash flow | $13.67M | $-10.79M | $-15.62M | $-4.49M | $-8.51M | $-30.44M | $-30.06M | $-43.46M | $-52.13M | $-39.31M | $-57.50M | $-46.54M | $-34.90M | $-31.11M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $52.89M | $-8.40M | $-6.76M | $83.88M | $85.99M | $-51.72M | $-21.17M | — | — | — | — |